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Abstract 
Background: Altered kallikrein-related peptidase activity and bradykinin are associated with skin disorders in 
humans and mice under chronic inflammation conditions. The bradykinin B1 receptor (B1R), also known as one of 
the G-protein-coupled receptor family and usually absent in intact tissues and upregulated during tissue injury, is 
responsible for vasodilation, capillary permeability, nociceptor sensitization, and pain; it is indispensable for physi-
opathological progress in chronic inflammation conditions, but its roles and effectors in the itching sensation of the 
allergic contact dermatitis model are poorly defined.
Results: We focused on incurable itching in a diphenylcyclopropenone (DCP) chronic inflammation experimental 
model. Preventive treatment with the B1R antagonist R892 significantly suppressed spontaneous scratching, while 
the B2R selective antagonist did not. B1R expression in the skin tissues of this model was detected using a quantita-
tive, real-time polymerase chain reaction, Western blotting, and immunohistochemistry; B1R mRNA and protein levels 
were increased compared with a sham-treated control group. A higher B1R IHC staining signal was observed in the 
keratinocytes in DCP-treated mice compared with a vehicle-treated group, so we studied the B1R function when 
superimposed on a protease-activated receptor 2 (PAR2) background, establishing B1R as a pivotal mediator of PAR2 
function in HaCaT cell lines.
Conclusion: Our data provide evidence that B1R facilitates the chronic itching sensation related to keratinocytes in a 
DCP-treated chronic inflammation experimental model.
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Background
Atopic dermatitis (AD) is accompanied by a disturbance 
of sensitization, which indicates the impact of chronic 
inflammation on the peripheral sensory neurons. AD 
patients and the animal model show increased and per-
sistent pruritus or itching like scratching behaviors.
Recently, it was suggested that bradykinin (BK) is 
involved in the pathological aggravation of AD, since 
activation of plasma kallikrein and the secretion of skin 
tissue kallikrein increase in human AD patients [1]. 
Two kallikreins (plasma and tissue) cleave kininogens to 
release kinins, including BK and kallidin (Lys-BK), both 
of which are converted to des-Arg derivatives by car-
boxypeptidase N or M and become BK receptor 1 (B1R) 
agonists [2]. BK is a mediator of inflammation; is pro-
duced from the plasma precursor kininogen by tissue 
injury, anoxia, or inflammation; and is responsible for 
nociceptor sensitization and pain, vasodilation, and cap-
illary permeability [3–6]. Furthermore, it is reported that 
BK participates in the release of some europeptides such 
as substance P indirectly [7]. Robust calcium transients 
are observed in the presence of BK in primary dorsal root 
ganglia (DRG) culture [8].
Whether BK participates in the chronic itch progress 
directly on the peripheral nerve endings or indirectly 
is not known. It is known, however, that B1R and BK 
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receptor 2 (B2R) are G protein-coupled receptors that 
mediate kinin effects. In normal skin, B2R signaling pre-
dominates, however, and cutaneous inflammation results 
in enhanced B1R responses.
Our previous studies have shown that itching is 
induced by BK, and the activation of kinin B1 receptor 
mediates the alloknesis response in complete Freund’s 
adjuvant (CFA)-inflamed mice [9]. At the same time, in 
the epithelium of patients with asthma, B1R is up regu-
lated and associated with airborne allergens that may play 
a role in the pathophysiology of atopic and allergic dis-
eases [10]. Stadnicki has suggested that B1R mRNA and 
protein increase in specimens from inflammatory bowel 
disease (IBD) patients and the enhanced B1R expression 
is related to the pathology of IBD [11, 12]. Nevertheless, 
a litter study on the itching sensation reported high B1R 
expression, focused on chronic itching in AD. Whether 
the expression of B1R changes and whether B1R expres-
sion is related to the etiology and development of the 
itching sensation in a chronic inflammatory state remains 
unclear.
A recent report has indicated that treatment with 
diphenylcyclopropenone (DCP) often results in contact 
dermatitis, as well as intense itching, in both humans and 
mice [13, 14]. If this is the case, DCP-treated mice can 
be considered as a chronic inflammatory in vitro model. 
We focus on B1R function on itching behaviors in DCP-
treated mice.
In the present study, we evaluated scratching behav-
iors in a mouse model of AD, especially focusing on (1) 
whether B1R affects itching behaviors and peripheral 
sensory neurons directly, and (2) its possible regula-
tory mechanism in up regulating B1R. For this purpose, 
we investigated the significance of B1R based on the 
behavior of the animal model and the skin tissues 
detected by immunohistochemistry. We then explored 
the possible regulatory activity of B1R by correlating 
B1R expression with keratinocytes dysfunction. We 
also tried to find out whether B1R is an independent 
factor in differentiating and proliferating in chronic 
inflammatory conditions.
Results
Antagonism of B1R significantly inhibited scratching 
in DCP‑treated animals, while selective antagonist of B2R 
did not
Pruritus symptoms produced following repeated applica-
tion of 1 % DCP (Aldrich Chemical Co, Milwaukee, WI, 
USA) was characterized by a pronounced and long-last-
ing increase in spontaneous scratching behavior by the 
hind paw (Fig.  1a). This process was observed starting 
on day 3, reaching a maximum on day 10 after repeated 
application of 1  % DCP on the seventh day (the results 
were not shown).
Interestingly, preventive treatment with B1R antagonist 
R892 (500 µg/kg, IP, 30 min before observation) (Fig. 1b), 
kallikrein inhibitor NFM (10  mg/kg, IP, 30  min before 
observation) (Fig. 1c) significantly suppressed spontane-
ous scratching compared with the sham-treated group. 
However, preventive treatment with B2R antagonist 
HOE-140 (300  nmol/kg, IP, 30  min before observation) 
during the same phase (Fig.  1d), did not significantly 
inhibit the scratching. Generally speaking, antagonism 
of B1R significantly inhibited scratching in DCP-treated 
animals.
Recently, a study unexpectedly reported that activa-
tion of B1R ameliorates autoimmune encephalomyelitis 
development [15]. For this reason, we assessed whether 
the activation of B1R could play a role in maintaining and 
promoting spontaneous, DCP-induced scratching.
Fig. 1 Scratching behaviors in 30 min of DCP-treated mice. Test substances were administered 30 min before observation. Graph showing 
increased spontaneous scratching of animal model in DCP-treated group (a). Preventive treatment with B1R antagonist R892 (b), kallikrein inhibi-
tor NFM (c) significantly suppressed spontaneous scratching compared with sham-treated group (n = 8), and was significantly different from the 
vehicle group, while B2R antagonist HOE-140 (d) did not. *P < 0.05 as determined by the Student t test
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B1R is up regulated in the skin of DCP‑treated mice
To evaluate the effects of DCP on the expression of kinin 
B1 receptors, the mRNA and protein level from the skin 
of control and DCP-treated mice (on day 10 post appli-
cation) were evaluated by means of real-time RT-PCR 
and Western blot assays, respectively. Basal expression 
of B1R was detected in the control group, while 10 days 
after DCP application, protein (Fig. 2a) and mRNA levels 
(Fig. 2b) of kinin B1R transcript were markedly increased 
in the skin tissue.
These results suggest that kinin B1 receptors exert 
an important role in the neuropathic hypersensitivity 
induced by DCP treatment.
DCP treatment induced up regulation of B1R expression 
on keratinocytes, while delocalized with known neuronal 
maker protein gene product 9.5 (PGP9.5)
Previous evidence showed that thoracic spinal cord 
astrocytes bear the B1R in STZ-diabetic rats [16]. After 
acquiring all these data, we still had an unanswered 
question: Does the neural ending express B1R during 
the development of AD? For this purpose, we meas-
ured the colocalization of B1R expression with a well-
known neural marker, PGP9.5, in the skin after DCP 
treatment. As shown in Fig.  3, little signal of B1R was 
detected in the PGP9.5 positive areas from treated 
mouse skin; nonetheless, B1R staining signal were 
markedly increased in keratinocytes at 10  days follow-
ing DCP-treated (Fig.  4a) compared to a sham treated 
group (Fig. 4b). There were also other cells showing B1R 
signals in the dermis. These results support the con-
cept that keratinocytes expressed and up regulated B1R 
expression after DCP treatment.
Thus, our data suggest that B1R primarily expressed 
in the keratinocytes after DCP treatment plays a rele-
vant role in modulating scratching behaviors induced by 
DCP-treated in mice.
B1R expression was induced when HaCaT cells were 
exposed to PAR2 agonist
Because mouse models suggest roles for B1R in keratino-
cytes, we hypothesized that kallikrein-related peptidase 
or cytokines in chronic inflammation would induce B1R 
production in a human keratinocyte cell line, HaCaT. 
A recent report has indicated that PAR-2, as a sensor 
for endogenous as well as exogenous proteases, plays 
numerous physiological and pathophysiological roles in 
the skin [17–19]. Sang Eun Lee reported activation of 
PAR2 in the lesional skin of AD led to the production of 
cytokines and chemokines involved in inflammation and 
Fig. 2 B1R is up regulated in skin tissues of DCP-treated group. Western blot (a) and RT-PCR (b) analysis of B1R in skin tissues obtained from sham 
(control) and DCP-treated mice. Protein expression (a) and PCR product (b) obtained with the specific B1R and β-tubulin antibodies or B1R and 
GAPDH primers. Insets (a upper panels) show a representative band of the protein expressed in both groups. Data were normalized against β-tubulin 
or GAPDH and expressed as the mean ± SEM of five independent mice. **P < 0.01 by the Student t test
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the itching sensation, and involved PAR2/MAPKs/NF-κB 
signal transduction pathways [20].
In this in vitro study, we evaluated the effects of PAR2 
agonist on the function of HaCaT cell lines (a keratino-
cyte like surface ectoderm-lineage cell line that natu-
rally expresses PAR1 and PAR2) especially focusing on 
whether (1) B1R is up regulated, (2) NF-κB is involved 
in regulating B1R expression, and (3) B1R is involved 
in differentiating and proliferating keratinocytes when 
superimposed on a PAR2 background. For this pur-
pose, we examined B1R regulating and the possible 
mechanism using a culture of HaCaT keratinocytes in 
the presence or absence of PAR2 agonist in a culture 
medium.
To study the effects of the PAR2 agonist, HaCaT 
keratinocytes were cultured with SLIGKV-NH2 
(100  μM) for approximately 24  h. By comparing B1R 
mRNA and protein levels with the control group, we 
confirmed that B1R expression was significantly aug-
mented (paired t test, P  <  0.05; Fig.  5b, d). A positive 
immunocytochemistry reaction for B1R was observed, 
located on the cell surface in HaCaT keratinocytes cells 
(Fig. 5a). In addition, SLIGKV-NH2 activated the NF-κB 
signaling pathway (Fig.  5c), while the NF-κB inhibitor 
(PDTC: 25  μM) intervened in the regulatory effects of 
PAR2 introducing B1R expression in HaCaT cells, fol-
lowing B1R down regulation (paired t test, P  <  0.05; 
Fig. 5b, d).
To understand B1R function on keratinocytes, we 
assessed whether the B1R antagonist could exert a sup-
pressing action on differentiation or proliferation of 
HaCaT cell lines. However, these outcomes appeared to 
occur independently of the epidermal barrier protein 
filaggrin, since its levels were not affected (the results 
were not shown). What is more, analysis of cell prolifera-
tion of HaCaT cells show that B1R antagonist R892 does 
not inhibit HaCaT cell growth by pretreatment of PAR2 
agonist (the results were not shown).
Discussion
Following the study of pain, we have spent much effort 
on the mechanism of acute and chronic itching in recent 
years, but more work is still required to explore the 
mechanisms and potential therapy of chronic itching.
We successfully built the AD animal model using DCP-
treated mice. Our present study showed that repeated 
DCP treatment resulted in spontaneous and intolerable 
itch-like scratching behaviors. The antagonist of B1 kinin 
receptors significantly inhibited scratching behavior in 
DCP-treated animals, while the B2R selective antagonist 
did not. We further confirmed that B1R mRNA and pro-
tein were elevated in skin tissues and clearly up regulated 
in DCP-treated mice compared with the vehicle-treated 
group. Moreover, a higher B1R staining signal was associ-
ated with keratinocyte hyperplasia in this model. Com-
bining B1R expression when superimposed on a PAR2 
background in a HaCaT cell (a keratinocytelike surface 
Fig. 3 Immunofluorescence images of skin tissues in DCP-treated mice. Serial sections of post-fixed skin tissues were used (a) showing representa-
tive IF images with antibodies to B1R (green) and the neuronal marker PGP9.5 (red), litter level of B1R was detected in the PGP9.5 positive areas, 
B1R expression alone (green) in keratinocytes or some dermis areas (b). A representative IF image with antibodies to PGP9.5 was used to observe 
morphology of skin
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ectoderm-lineage cell line that naturally expresses PAR1 
and PAR2) with our findings, we have reason to believe 
that B1R contributes to the itching sensation.
It has been reported that B1R is up regulated in various 
inflammatory states of the animal model [21–24]. In our 
recent study, the antagonist of B1 kinin receptors signifi-
cantly inhibited scratching in DCP-treated animals, while 
the B2R selective antagonist did not. We also observed a 
marked increase in B1R mRNA and protein levels in the 
mouse skin tissue 10 days after DCP treatment.
There is an increase in B1R protein expression in DRG 
neurons 1 day after CFA treatment [25]. Robust calcium 
transients are observed in the presence of the BK in the 
primary DRG culture. We sought to find out whether 
B1R expressed in the neural endings participated directly 
in the itching sensation. Next, we performed dou-
ble staining for B1R and the known neuronal marker 
PGP9.5. Confocal microscopic analysis showed that DCP 
treatment induced up regulation of B1R expression on 
the KC cell, while it was delocalized with known neu-
ronal maker PGP9.5 in the skin of DCP-treated mice. So 
it may function through other mechanisms in the periph-
eral innervations area of this animal model.
Several reports show that activation of G-protein 
coupled B2R/B1R correlate with various cell functions 
[26–29]. It has been reported that B1R is up regulated in 
various inflammatory states, some of which are mediated 
by cytokines such as IL-1 [30]. There are also data sug-
gesting that kinin B1R is up regulated by the oxidative 
stress in the brain of insulin-resistant rats, and its activa-
tion causes stereotypic nocifensive behavior through the 
release of substance P, glutamate, and nitric monoxide 
(NO) [21].
Increased B1R gene and protein expression in DCP-
treated mice provides a structural basis for the important 
role of BK in chronic inflammation. Here we confirmed 
Fig. 4 HE and IHC in mouse skin tissue. Sections of post-fixed mice skin tissues in DCP and vehicle-treated group immunostained with antibodies 
to B1R (a, b) showing that B1R staining signals were markedly increased in keratinocytes in DCP-treated mice. In photos of both groups, H&E stain-
ing was used to observe morphological and pathological changes
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that B1R was up regulated in keratinocytes in the skin of 
DCP-treated mice. Others have reported that keratinocytes 
produce and secrete various biologically active chemokines, 
cytokines, and trophic factors to regulate the expression 
and function of many ion channels in sensory neurons to 
promote hyperexcitability of sensory terminals [25, 31, 32].
It is thus suggested that the increase of B1R expres-
sion facilitates nocifensive behavior through the func-
tional changes in the keratinocytes, which are related 
by changes in the neuron-keratinocyte cross-talk in the 
peripheral innervation area.
We postulated that, if human AD resembled that of 
the rat, many of the same findings would occur in human 
keratinocyte as in experimental mice treated with DCP. 
PAR2 is a G-protein-coupled receptor (GPCR) and can be 
activated in response to various exogenous and endogenous 
proteases. We extended the findings and enhanced them by 
characterizing the cellular localization, protein, and mRNA 
of B1R after pretreatment with PAR2 agonist. In the present 
study, B1R expression was significantly augmented when 
pretreated with SLIGKV-NH2 in HaCaT cells; this demon-
stration is in agreement with our findings in mice.
Several studies show that PAR2/MAPKs/NF-κB signal 
transduction pathways are involved in PAR2 function 
[33–35]. The NF-κB family not only plays a pivotal role 
in inflammation, but also regulates various inflammation 
Fig. 5 B1R expressed in HaCaT cells on a PAR2 background. Positive immunocytochemistry reaction for B1R was observed and displaying 
membrane and cytosolic localization in HaCaT keratinocytes after 24-h incubation with vehicle (control), PAR2 agonist SLIGKV-NH2 (100 mM) (a). 
Representative images displaying nuclear localization of p65 (green) and DAPI (blue) in HaCaT keratinocytes after 24-h incubation with vehicle, 
SLIGKV-NH2 (100 mM) (c). Western blot of HaCaT cells following treatment with vehicle (control), SLIGKV-NH2 (100 mM). Samples were probed with 
antibodies against B1R and tubulin (b). B1R mRNA levels were also significantly augmented (d). Pretreatment with the NF-κB inhibitor PDTC (25 μM) 
prevented SLIGKV-NH2-induced B1R expression (b, d). Values represent mean ± SEM; *P < 0.05; **P < 0.01 by the Student t test
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factors. In view of the above results, we presented direct 
evidence that the PAR2 agonist promotes the expression 
of B1R in keratinocytes. To understand how this was 
accomplished, we explored the B1R expression in pyr-
rolidine dithiocarbamate (PDTC) treatment. SLIGKV-
NH2 activated the NF-κB signaling pathway, and at the 
same time under PDTC treatment, B1R expression was 
decreased because of the blocking of the NF-κB signal 
transduction pathways.
Searching further for related mechanisms, we found 
that NF-κB signal pathway activity has an important 
role in this process. Where PAR2 activation promoted 
B1R expression, NF-κB inhibitor PDTC decreased B1R 
expression when pretreatment with SLIGKV-NH2. 
Under these circumstances, the effects of PAR2 may rely 
on the NF-κB signal pathway.
Considering the present findings and the above-men-
tioned reports, we believe that the NF-κB signal pathway 
has an important role in B1R expression in keratinocytes.
In view of the above results, we assumed that B1R up 
regulation exerted an important role in the itching sen-
sation in chronic inflammation. To understand how this 
is accomplished, we explored the role of B1R in differ-
entiating or proliferating HaCaT cell lines. In the pre-
sent study, analysis of cell proliferation and the gene 
expression profile of epidermal differentiation markers 
of HaCaT cells show that B1R antagonist R892 cannot 
inhibit HaCaT cell growth and proliferation by the pre-
treatment of PAR2 agonist (results not shown). It has 
been shown that Klk8 is involved in the differentiation 
of keratinocytes through up regulation and activation of 
PAR2 in the late stages of wound healing and prolifera-
tion in the early stages [1]. There are also studies on B1R 
function in the expression of cytokines or signal mole-
cules, such as PGE2 and NO [36–39]. So, different stages 
in the pathologic and physiologic changes in chronic 
inflammation may relate to B1R function, which needs 
further study.
Elevation of kallikrein and BK levels has been well 
demonstrated in chronic inflammatory conditions. Simi-
larly, we showed how B1R mRNA and protein expression 
was up regulated in the skin of an experimental animal 
model. In allergic contact dermatitis with inflammation, 
B1R may promote scratching as follows: (1) B1R is up 
regulated in keratinocytes, (2) keratinocytes can also be 
seen as a “sensory forefront” of neuronal activation and 
signaling, (3) subsequently, active B1R in the keratino-
cytes enhances neural sensitization to indirectly promote 
chronic itching sensations.
In conclusion, the present results indicate that B1R 
facilitates the chronic itching sensation related to 
keratinocytes in a DCP-treated chronic inflammation 
experimental model. How exactly this increase of B1R 




Male C57BL/6J mice (20–22  g) were used in this study. 
The dorsal hair of the mice was removed and then stim-
ulated for the first day and the seventh day with DCP 
repeatedly under conventional conditions. Animal sam-
ples comprising skin tissues were obtained from experi-
mental models of chronic inflammation induced by DCP 
and vehicle-treated mice at the animal center of South-
Medical University or Sun Yat-Sen University Cancer 
Center, Guangzhou, China. The experimental procedures 
and animal use and care protocols were approved by the 
Committee on Ethical Use of Animals at the Guangdong 
Academy of Medical Sciences (Guangzhou, China), fol-
lowing the National Institutes of Health’s animal use and 
care guidelines.
The reagents used in  vivo experiment including: DCP 
was purchased from Aldrich Chemical Co (Milwau-
kee, WI, USA). The selective B1R antagonist [Ac-Lys-
Arg-Pro-Pro-Gly-(αMe)Phe-Ser-DβNal-IIe, R892] were 
purchased from Tocris Bioscience (Ellisville, MI, USA). 
Kallikrein inhibitor NFM, the selective B2R antagonist 
(Arg-Arg-Pro-Hyp-Gly-Thi-Ser-Tic-Oic-Arg, Hoe140), 
were obtained from Sigma Chemical Co. (Saint Louis, 
MO, USA). All chemicals were dissolved according to 
the manufacturer’s instructions for stock solutions and 
stored at −20 °C. These chemicals were diluted with NS 
or miliQ H2O to obtain a working solution just before 
use.
Immunohistochemistry and immunocytochemistry
We examined skin tissues from experimental models of 
chronic inflammation induced by DCP including five 
paired specimens. Immunohistochemical (IHC) stain-
ing of those tissues was analyzed. Paraffin-embedded and 
formalin-fixed samples were cut into 4-μm sections, IHC 
staining was performed after dewaxing, 10-min incuba-
tion was done with 3 % H2O2 to block endogenous perox-
idase, and 25-min microwave antigen was retrieved with 
B1R antibody (1:500; Biorbyt Ltd, Cambridge, UK) at 4 °C 
overnight. This was followed by horseradish peroxidase 
(HRP)-labeled secondary antibody incubation and diam-
inobenzidine chromogenic reaction in a GT Vision III 
Detection System/Mo Rb (GeneTech, Shanghai, China). 
Thereafter, the tissue sections were scanned using multi-
ple spectral microscopy.
For immunocytochemistry analysis, the HaCaT 
keratinocytes were fixed, permeablized, and then 
incubated with an ant-NF-κB p65 antibody (1: 400; 
Cell Signaling, MA, USA), followed by an Alexa Fluor 
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488-conjugated anti-rabbit IgG (Molecular Probes, 
Eugene, OR, USA). Paraffin-embedded samples were 
processed for immunofluorescence as previously 
described for immunohistochemistry, the sections were 
incubated with an antibody against B1R antibody (1: 
500; Biorbyt Ltd, Cambridge, UK) and PGP9.5 (1:500; 
Abcam, Cambridge, Mass, USA) for double staining; 
this was followed by an Alexa Fluor 488-conjugated 
anti-rabbit IgG (Molecular Probes) and Alexa Fluor 
546-conjugated anti-mouse IgG (Molecular Probes). 
Nuclei were stained with 4′,6-diamidino-2-phenylindole 
(DAPI). Slides were mounted with antifade mounting 
medium, dried for 24 h at room temperature, and then 
stored at 4 °C for future use. Images were captured and 
analyzed using an Olympus FV1000 confocal laser scan-
ning microscope (Olympus America, Center Valley, PA, 
USA).
Western blot
Protein of skin tissues of mice was extracted with Pro-
teoJET Mammalian Cell Lysis Reagent (KeyGen Biotech 
Co, Nanjing, China) supplemented with protease inhibi-
tor for 10 min on ice. The human HaCaT keratinocytes 
were washed three times with phosphate buffered saline 
(PBS), then the pellets were resuspended in lysis buffer 
supplemented with protease inhibitor for 10 min on ice. 
After centrifugation at 10,000×g for 15 min, the super-
natants were dissolved in Loading Buffer and heated at 
96 °C for 10 min, resolved on 8 % Tris–HCl polyacryla-
mide gels, and transferred to a nitrocellulose membrane. 
The membranes were blocked with 5 % BSA. Overnight 
incubation (4  °C) of the primary antibody was followed 
by HRP-conjugated anti-rabbit (1:5000; Novus Bio-
logicals, Littleton, CO, USA) or anti-mouse antibody 
(1:1000; Novus Biologicals) and Pierce ECL Western 
Blotting Substrate (Thermo Fisher Scientific, Bothell, 
WA, USA). Antibody dilution was as follows: B1R (1:500, 
Santa Cruz, CA, USA); β-tublin (1:1000, Cell Signaling, 
MA, USA).
Quantitative real‑time PCR
The skin tissues were treated with RNAlater, (Life Tech-
nologies, Carlsbad, CA, USA) followed by liquid nitro-
gen refrigeration were collected. The cultured cells were 
digested by 0.25  % trypsin-ethylene diaminetetraacetic 
acid (Life Technologies) and washed twice with PBS before 
homogenizing. Total RNA was extracted using TRIzol (Life 
Technologies) according to the manufacturer’s instructions. 
Relative BDKRB1/Bdkrb1 mRNA expression levels were 
analyzed by qRT-PCR with double-stranded, DNA-binding 
dyes as reporters, using GoTaq qPCR Master Mix (Pro-
mega, Madison, WI, USA). Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) mRNA expression was used 
as the internal reference. RT-PCR primers were: Bdkrb1 
forward: 5’-CCCAACTACAGTTGTGAACGC-3’, Bdkr-
b1reverse: 5’-AGGATGATGCCATGCACAGT-3’; Gapdh 
forward: 5’-CTCCTCCTGTTCGACAGTCAGC-3’; Gapdh 
reverse: 5’-CCCAATACGACCAAATCCGTT-3’; BDKRB1 
forward: 5’-GGCAGCTTCTGATCTGGTGT-3’, BDKRB1 
reverse: 5’-GTAGCGGTCCTGACTGATGG-3’; GAPDH 
forward: 5’-GTGTTCCTACCCCCAATGTGT-3’; GAPDH 
reverse: 5’-TGAAGTCGCAGGAGACAACC-3’.
Cell lines
The human HaCaT keratinocytes were cultured in Dul-
becco’s modified Eagle’s medium (Life Technologies) 
supplemented with 10  % fetal bovine serum (FBS; Life 
Technologies). Cell lines were incubated at 37 °C with 5 % 
CO2 and 95 % humidity. All cells were obtained from Cell 
Bank, Shanghai Institutes for Biological Sciences (Shang-
hai, China).
The reagents used in vitro experiment including: PAR2 
agonist, Ser-Leu-lle-Gly-Lys-Val-NH2 (SLIGKV-NH2) 
were purchased from Tocris Bioscience (Ellisville, MI, 
USA); NF-κB inhibitor pyrrolidine dithiocarbamate 
(PDTC) was obtained from Sigma Chemical Co. (Saint 
Louis, MO, USA). All chemicals were dissolved accord-
ing to the manufacturer’s instructions for stock solutions 
and stored at −20 °C. These chemicals were diluted with 
miliQ H2O to obtain a working solution just before use.
Statistical analysis
Data are shown as mean ±  SEM. The statistical signifi-
cance of differences between groups was determined by 
Student’s t test. All data were analyzed using two-tailed 
tests unless otherwise specified (*P  <  0.05; **P  <  0.01; 
***P < 0.001).
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